Drug
Alvelestat clinical trials
Also written AZD9668 and MPH966.
- studies test it
- 17
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2009 (4)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 5
AstraZeneca (11) · University of Alabama at Birmingham (2) · National Cancer Institute (NCI) (1) · Mereo BioPharma (1) · Nick Giannoukakis, PhD (1) · Nelson Chao (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses alvelestat is read from its arms, and is right about nine times in ten.
Testing it · 17
- Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT02669251Written as MPH966
- Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin DeficiencyCompletedPhase 2University of Alabama at BirminghamNCT03679598Written as Alvelestat (MPH966)
- COVID-19 Study of Safety and Tolerability of AlvelestatCompletedPhase 1/2University of Alabama at BirminghamNCT04539795Written as Alvelestat
- A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.CompletedPhase 2Mereo BioPharmaNCT03636347Written as Alvelestat oral tablet - dose 1
- Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 DiabetesCompletedPhase 2Nick Giannoukakis, PhDNCT02597101Written as AZD9668
- MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell TransplantationWithdrawnPhase 1/2Nelson ChaoNCT03986086Written as MPH966
- AZD9668 Relative BioavailabilityCompletedPhase 1AstraZenecaNCT01035411Written as AZD9668
- A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of WarfarinWithdrawnPhase 1AstraZenecaNCT01214122Written as AZD9668
- A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic FibrosisCompletedPhase 2AstraZenecaNCT00757848Written as AZD9668
- A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With BronchiectasisCompletedPhase 2AstraZenecaNCT00769119Written as AZD9668
- Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2AstraZenecaNCT01054170Written as AZD9668
- Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/FormoterolCompletedPhase 2AstraZenecaNCT01023516Written as AZD9668
- A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With TiotropiumCompletedPhase 2AstraZenecaNCT00949975Written as AZD9668
- A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2AstraZenecaNCT00703391Written as AZD9668
- Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy SubjectCompletedPhase 1AstraZenecaNCT01161355Written as AZD9668
- Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male VolunteersCompletedPhase 1AstraZenecaNCT01147549Written as [C14]AZD9668
- AZD9668 Relative BioavailabilityCompletedPhase 1AstraZenecaNCT01034982Written as AZD9668
Codes
What other systems call alvelestat · ClinicalTrials.gg INT005922
- UNII (FDA) 6Y5629322XALVELESTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27074417alvelestatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C125714AlvelestatOne source FDA
- DrugBank DB11863One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6Y5629322X | ALVELESTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074417 | alvelestat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C125714 | Alvelestat | One source FDA |
| DrugBank | DB11863 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.